Evidence map›Paper›PMID 38236369›Full record

ArticleInternational journal of hematology2024

A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.

Kana Kato, Shinsuke Takagi, Hirofumi Takano, Shinichi Tsunoda, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida and 9 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Deletion mutations of theHaematologica · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Kana KatoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Shinsuke TakagiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan. shinsuke-takagi@umin.net.ORCID http://orcid.org/0000-0003-0441-393X
Hirofumi TakanoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Shinichi TsunodaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Otoya WatanabeDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Kyosuke YamaguchiDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Kosei KageyamaDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Yuki TayaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Kazuya IshiwataDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Hisashi YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Yuki Asano-MoriCenter for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan.
Yukako KoikeDepartment of Clinical Laboratory, Toranomon Hospital, Tokyo, Japan.
Shigeyoshi MakinoJapanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan.
Atsushi WakeDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-0001, Japan.
Toranomon Hospital · JPJapanese Red Cross Society, Japan · JPOkinaka Memorial Adult Disease Research Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired point mutations in the ABL1 gene are widely recognized as a cause of Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia (Ph

Indexed as

Fusion Proteins, bcr-ablPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansMutationPhiladelphia ChromosomePoint MutationProtein Kinase InhibitorsProto-Oncogene Proteins c-ablABL1 protein, humanFusion Proteins, bcr-ablProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPartial deletion type mutationPhiladelphia chromosome-positive B cell precursor acute lymphoblastic leukemiaTruncated ABL1 mutation

Identifiers

PMID38236369
OpenAlexW4390964417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.